Mild to moderate hyperhomocysteinaemia in cardiovascular disease

Acta Cardiologica

Volumn 53, Issue 6, 1998, Pages 337-344

  De Vriese, An S ^a   De Sutter, Johan H ^a   De Buyzere, Marc ^a   Duprez, Daniel ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Atherosclerosis; Homocysteine; Risk factor; Screening; Thrombosis; Treatment

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE; OXYGEN RADICAL; VITAMIN B GROUP;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; HUMAN; HYPERHOMOCYSTEINEMIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CONTROLLED CLINICAL TRIALS; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; INCIDENCE; MALE; RISK FACTORS; THROMBOSIS; VITAMINS;

EID: 0032449527     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. McCully KS. Vascular pathology of homocyst(e)inemia: implications for the development of arteriosclerosis. Am J Pathol 1969; 56: 111-128.
2. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, ed. Atherosclerotic Cardiovascular Disease, Hemostasis and Endothelial Function. New York: Marcel Dekker Inc, 1992: 183-236.
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
4. Verhoef P, Stampfer MJ. Prospective studies of homocysteine and cardiovascular disease. Nutr Rev 1995; 53: 283-288.
5. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Int Med 1998; 158: 2101-2106.
6. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PE, Palma-Reis RJ et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-1781.
7. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7.
8. Stipanuk MH. Metabolism of sulfur-containing amino acids. Ann Rev Nutr 1986; 6: 179-209.
9. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver C, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. 7th ed. Vol 1. New York: McGraw-Hill, 1996: 1279-1327.
10. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and applications. Clin Chem 1993; 39: 1764-1773.
11. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM, Kvale G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-1533.
12. Dennis VW, Nurko S, Robinson K. Hyperhomocysteinemia: detection, risk assessment and treatment. Current Opinion in Nephrology and Hypertension 1997; 6: 483-488.
13. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nntr 1992; 12: 279-298.
14. Anderson A, Brattström L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992; 22: 79-87.
15. Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from The NHLBI Family Heart Study. Atherosclerosis 1995; 116: 147-151.
16. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Carcliol 1996; 27: 517-527.
17. Garg UC, Zheng ZJ, Folsom AR, Moyer YS, Tsai MY, McGovern P, Eckfeldt JH. Short-term and long-term variability of plasma homocysteine measurement. Clin Chem 1997; 43: 141-145.
18. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PW. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-715.
19. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
20. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, van Oost BA, den Heijer M, Stevens EM, Trijbels JM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
21. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-421.
22. Frosst P, Blom HJ, Milos R, Sheppard CA, Matthews RG, Boers GH, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
23. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow R, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-2416.
24. Guttormsen AB, Ueland PM, Nesthus I, Nygard O, Schneede J, Vollset SE, Refsum H. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥ 40 μmol/l). The Hordaland Homocysteine Study. J Clin Invest 1996; 98: 2174-2183.
25. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10-20.
26. Verhoef P, Kok FJ, Kluijtmans LA, Blom HJ, Refsum H, Ueland PM, Kruyssen DA. The 677C-T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 1997; 132: 105-113.
27. Harmon DL, Woodside JV, Yarnell JW, McMaster D, Young IS, McCrum EE, Gey KF, Whitehead AS. The common "thermolabile" variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia. Q J Med 1996; 89: 571-577.
28. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, Psaty BM, Longstretch WT, Koepsell TD, Raghunathan TE, Reitsma PH. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96: 412-417.
29. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-2698.
30. Miller JW, Nadeau MR, Smith D, Selhub J. Vitamin B-6 deficiency vs folate deficiency: comparison of responses to methionine loading in rats. Am J Clin Nutr 1994; 59: 1033-1039.
31. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992; 55: 131-138.
32. Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJ. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996; 98: 177-184.
33. 6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation 1998; 97: 437-443.
34. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal failure. Kidney Int 1996; 50 (Suppl 57): S11-S17.
35. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40: 230-234.
36. Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M, Seyoum E, Hartman W, Prior R, Wilson PW, Selhub J. Hyperhomocysteinemia and traditional cardiovascular risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93-103.
37. Bostom A, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995; 116: 59-62.
38. Guttormsen AB, Svarstad E, Ueland PM, Refsum H. Elimination of homocysteine from plasma in subjects with end-stage renal failure. Ir J Med Sci 1995; 164(Suppl 15): 8-9.
39. Chauveau P, Chadefaux B, Coudé M, Aupetit J, Hannedouche T, Kamoun P, Jungers P. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43(Suppl 41): S72-S77.
40. Soria C, Chadefaux B, Coudé M, Gaillard O, Kamoun P. Concentrations of total homocysteine in plasma in chronic renal failure. Clin Chem 1990; 36: 2137-2138.
41. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
42. Blom HJ, Kleinveld HA, Boers GH, Demacker PN, Hak-Lemmers HL, Poele-Pothoff MT, Trijbels JM. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinemia. Eur J Clin Invest 1995; 25: 149-154.
43. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res 1993; 34: 2051-2061.
44. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 270: 319-324.
45. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 24-29.
46. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993; 22: 854-858.
47. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metriweli C, Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-2544.
48. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation 1997; 95: 1119-1121.
49. Matthias D, Becker CH, Riezler R, Kindling PH. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis 1996; 122: 201-216.
50. Blann AD. Endothelial cell damage and homocysteine. Atherosclerosis 1992; 94: 89-91.
51. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741.
52. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-6373.
53. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
54. Dudman NP, Wileken DE, Stocker R. Circulating lipid hydroperoxide levels in human hyperhomocysteinemia. Relevance to development of arteriosclerosis. Arterioscler Thromb 1993; 13: 512-516.
55. Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenetic mechanisms predisposing to thrombosis. J Nutr 1996; 126: 1285S-1289S.
56. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-1082.
57. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-1953.
58. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994; 25: 1924-1930.
59. Alfthan G, Pekkanen J, Jauhiainen M, Pitkäniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.
60. Franken DG, Boers GH, Blom HJ, Trijbels FJ, Kloppenborg PW. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994; 14: 465-470.
61. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE, Kutner M, Topol EJ, Jacobsen DW. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825-2830.
62. Bots ML, Launer LJ, Lindemans J, Hofman A, Grobbee DE. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study. J Int Med 1997; 242: 339-347.
63. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.
64. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.
65. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-291.
66. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995; 332: 328-329.
67. Ubbink JB, Vermaak WJ, Bennet JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr 1991; 69: 527-534.
68. Taylor LM, DeFrang RD, Harris EJ, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991; 13: 128-136.
69. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase. Thromb Haemost 1997; 78: 523-526.
70. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, Evans A, Graham IM, Whitehead AS. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996; 94: 2154-2158.
71. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis 1996; 121: 293-294.
72. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation ala677-val in the methylenetetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997;77:818-821.
73. De Francis R, Mancini FP, D'Angelo A, Sebastio G, Fermo I, De Stefano V, Margaglione M, Mazzola G, Di Minno G, Andria G. Elevated total plasma homocysteine and mutation in 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Human Genet 1996; 58: 262-264.
74. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine and ischemic cerebrovascular disease. Stroke 1997; 28: 1739-1743.
75. van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997; 95: 21-23.
76. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57: 1098-1102.
77. Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz GA, Spiegelman D, Willett WC, Hunter DJ. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996; 56: 4862-4864.
78. 12 deficiency than in heterozygosity for homocystinuria due to cystathionine β-synthase deficiency. Metabolism 1988; 37: 175-178.
79. Ubbink JB, Vermaak WJ, van der Merwe A, Decker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994; 124: 1927-1933.
80. Arnadottir M, Brattstrom L, Simonsen O, Thysell H, Hultberg B, Andersson A, Nilsson-Ehle P. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993; 40: 236-240.
81. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer L. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985; 37: 1-31.
82. Omenn GS, Beresford SA, Motulsky AG. Preventing coronary heart disease. B vitamins and homocysteine. Circulation 1998; 97: 421-424.